Loading…
Reported covered position: Government Relations Associate
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2011 · first_quarter · Q1
Infectious diseases; drug, diagnostics and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Preservation of Antibiotics for Medical Treatment Act; Generating Antibiotic Incentives Now Act; Strategies to Address Antimicrobial Resistance (STAAR).
Source: Senate LDA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S. 619; Strategies to Address Antimicrobial Resistance (STAAR) Act.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Strategies to Address Antimicrobial Resistance Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Strategies to Address Antimicrobial Resistance Act
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S. 619; Strategies to Address Antimicrobial Resistance (STAAR) Act.
Preservation of Antibiotics for Medical Treatment Act of 2009
Client: INFECTIOUS DISEASES SOCIETY OF AMERICA · Firm: INFECTIOUS DISEASES SOCIETY OF AMERICA
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · fourth_quarter · Q4
Medical liability; antimicrobial resistance research; infectious diseases product research and development; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; and support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; antimicrobial stewardship; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.R. 2400.
Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · third_quarter · Q3
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S.619; Strategies to Address Antimicrobial Resistance (STAAR) Act H.r. 2400.
Medical Liability; Antimicrobial resistance research; Infectious diseases product research and development; Regulatory science; Unnecessary regulatory burdens placed on medical research; laboratory developed tests; Comparative effectiveness research; and Support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority (BARDA), Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · second_quarter · Q2
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Regulatory science; Unnnecessary regulatory burdens placed on medical research; laboratory developed tests; and Support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Office of the Biomedical Advance Research and Development Authority (BARDA), Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administraton and global programs for various infectious diseases related issues.
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; PAMTA H.R. 1549/S. 619; Strategies to Address Antimicrobial Resistance (STAAR) Act.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2010 · first_quarter · Q1
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · 4A
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Infectious diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance (STAAR) Act.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · 4A
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens places on medical research; Support for evidence-based decision making.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · Q4
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquistion Program; and Healthcare Reform.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · third_quarter · Q3
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · second_quarter · Q2
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · first_quarter · Q1
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisiton Program
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2009 · fourth_quarter · Q4
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquistion Program
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2008 · fourth_quarter · 4A
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquistion Program
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2008 · third_quarter · Q3
Medical liability; Antimicrobial resistance research; infectious diseases product research and development.
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hopsital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2008 · second_quarter · Q2
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
Funding support for the Centers for Diseases Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2008 · first_quarter · Q1
Medical liability; Antimicrobial resistance research; infectious diseases product research and development.
Funding support for the Centers for Diseases Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; immunizations; pandemic influenza, public health security and bioterrorism; global infectious diseases; biomedical research, Ryan White reauthorization; Lyme disease and other infectious diseases issues.
INFECTIOUS DISEASES SOCIETY OF AMERICA via INFECTIOUS DISEASES SOCIETY OF AMERICA
2007 · year_end · YA
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; immunizations; pandemic influenza, public health security and bioterrorism; global infectious diseases; biomedical research, Ryan White Reauthorization; Lyme disease and other infectious diseases issues.
Medical liability; Antimicrobial resistance research; infectious diseases product research and development.
Funding support for the Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Depatment of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; Antimicrobial resistance research; infectious diseases product research and development; Unnecessary regulatory burdens placed on medical research; Support for evidence-based decision making.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Medical liability; Antimicrobial resistance research; infectious diseases product research and development
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Funding support for the Department of Health and Human Services, Centers for Diseases Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration and global programs for various infectious diseases related issues.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquistion Program
Medical liability; Antimicrobial resistance research; infectious diseases product research and development.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, U.S. Agency for International Development (USAID)
Reimbursement for outpatiend infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Reimbursement for outpatient infusion therapy; Physician payment cuts; Medicaid and Medicare Reform, including Medicare Prescription Drug Coverage; Average Sales Price; and Competitive Acquisition Program
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE